Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1997 1
1998 2
2001 1
2002 2
2003 4
2004 3
2005 1
2006 2
2007 2
2008 5
2009 6
2010 5
2011 2
2012 4
2013 1
2014 7
2015 8
2016 7
2017 7
2018 5
2019 3
2020 5
2021 6
2022 4
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

81 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Basal cell carcinoma, susceptibility to, 1"
Page 1
Basal Cell Carcinoma Review.
Kim DP, Kus KJB, Ruiz E. Kim DP, et al. Hematol Oncol Clin North Am. 2019 Feb;33(1):13-24. doi: 10.1016/j.hoc.2018.09.004. Hematol Oncol Clin North Am. 2019. PMID: 30497670 Review.
Basal cell carcinoma (BCC) is the most common malignancy and the incidence is rising. ...
Basal cell carcinoma (BCC) is the most common malignancy and the incidence is rising. ...
Germline intergenic duplications at Xq26.1 underlie Bazex-Dupre-Christol basal cell carcinoma susceptibility syndrome.
Liu Y, Banka S, Huang Y, Hardman-Smart J, Pye D, Torrelo A, Beaman GM, Kazanietz MG, Baker MJ, Ferrazzano C, Shi C, Orozco G, Eyre S, van Geel M, Bygum A, Fischer J, Miedzybrodzka Z, Abuzahra F, Rübben A, Cuvertino S, Ellingford JM, Smith MJ, Evans DG, Weppner-Parren LJMT, van Steensel MAM, Chaudhary IH, Mangham DC, Lear JT, Paus R, Frank J, Newman WG, Zhang X. Liu Y, et al. Br J Dermatol. 2022 Dec;187(6):948-961. doi: 10.1111/bjd.21842. Epub 2022 Sep 12. Br J Dermatol. 2022. PMID: 35986704
What is already known about this topic? Bazex-Dupre-Christol syndrome (BDCS) is a rare X-linked basal cell carcinoma susceptibility syndrome linked to an 11.4-Mb interval on chromosome Xq25-q27.1. ...ARHGAP36 may be a novel therapeutic target for all f …
What is already known about this topic? Bazex-Dupre-Christol syndrome (BDCS) is a rare X-linked basal cell carcinoma …
Basal cell carcinoma of the skin (part 1): epidemiology, pathology and genetic syndromes.
Correia de Sá TR, Silva R, Lopes JM. Correia de Sá TR, et al. Future Oncol. 2015 Nov;11(22):3011-21. doi: 10.2217/fon.15.246. Epub 2015 Oct 9. Future Oncol. 2015. PMID: 26449153 Review.
Basal cell carcinoma (BCC) is the most common skin cancer worldwide with increasing incidence, but difficult to assess due to the current under registration practice. ...BCC associate with several genetic syndromes, of which basal cell nevus syn …
Basal cell carcinoma (BCC) is the most common skin cancer worldwide with increasing incidence, but difficult to assess …
Nervous system (NS) Tumors in Cancer Predisposition Syndromes.
Patil P, Pencheva BB, Patil VM, Fangusaro J. Patil P, et al. Neurotherapeutics. 2022 Oct;19(6):1752-1771. doi: 10.1007/s13311-022-01277-w. Epub 2022 Sep 2. Neurotherapeutics. 2022. PMID: 36056180 Free PMC article. Review.
These fundamental discoveries have also broadened the horizon of novel therapeutic possibilities and have helped to be better predictors of prognosis and survival. The treatment paradigm of specific NS tumors may also vary based on the patient's cancer predispositio …
These fundamental discoveries have also broadened the horizon of novel therapeutic possibilities and have helped to be better predictors …
Epigenetic biomarkers in skin cancer.
Greenberg ES, Chong KK, Huynh KT, Tanaka R, Hoon DS. Greenberg ES, et al. Cancer Lett. 2014 Jan 28;342(2):170-7. doi: 10.1016/j.canlet.2012.01.020. Epub 2012 Jan 27. Cancer Lett. 2014. PMID: 22289720 Free PMC article. Review.
Genome-Wide Expression Difference of MicroRNAs in Basal Cell Carcinoma.
Wei HP, Zhan S, Zhu QA, Chen ZJ, Feng X, Chen JY, Zhang QL, Zhao J, Meng L. Wei HP, et al. J Immunol Res. 2021 Aug 4;2021:7223500. doi: 10.1155/2021/7223500. eCollection 2021. J Immunol Res. 2021. PMID: 34395634 Free PMC article.
Distinct expression of the miRNAs has rarely been explored in basal cell carcinoma (BCC) of skin, and the regulatory role of miRNAs in BCC development remains quite opaque. ...In particular, the "basal cell carcinoma pathways" were found …
Distinct expression of the miRNAs has rarely been explored in basal cell carcinoma (BCC) of skin, and the regulatory ro …
Disease risk scores for skin cancers.
Fontanillas P, Alipanahi B, Furlotte NA, Johnson M, Wilson CH; 23andMe Research Team; Pitts SJ, Gentleman R, Auton A. Fontanillas P, et al. Nat Commun. 2021 Jan 8;12(1):160. doi: 10.1038/s41467-020-20246-5. Nat Commun. 2021. PMID: 33420020 Free PMC article.
We trained and validated risk prediction models for the three major types of skin cancer- basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and melanoma-on a cross-sectional and longitudinal dataset of 210,000 consented research …
We trained and validated risk prediction models for the three major types of skin cancer- basal cell carcinoma ( …
The causal effects of atopic dermatitis on the risk of skin cancers: A two-sample Mendelian randomization study.
Luo M, Zheng Y, Zhuo Q, Lin L, Han Y. Luo M, et al. J Eur Acad Dermatol Venereol. 2024 Apr;38(4):703-709. doi: 10.1111/jdv.19674. Epub 2023 Nov 27. J Eur Acad Dermatol Venereol. 2024. PMID: 38009387
RESULTS: Inverse variance-weighted method showed that genetically predicted dermatitis patients were significantly associated with an increased incidence of basal cell carcinoma (OR, 1.20; 95% CI, 1.10-1.31; p = 4.07E-05) and cutaneous squamous cell …
RESULTS: Inverse variance-weighted method showed that genetically predicted dermatitis patients were significantly associated with an …
The Role of Anti-PD-1/PD-L1 in the Treatment of Skin Cancer.
Patrinely JR Jr, Dewan AK, Johnson DB. Patrinely JR Jr, et al. BioDrugs. 2020 Aug;34(4):495-503. doi: 10.1007/s40259-020-00428-9. BioDrugs. 2020. PMID: 32447657 Free PMC article. Clinical Trial.
Development of monoclonal antibodies to programmed cell death-1 receptor and its ligand (PD-1/PD-L1) have transformed the management of metastatic melanoma, squamous cell carcinoma, and Merkel cell carcinoma. ...Early reports suggest similar act …
Development of monoclonal antibodies to programmed cell death-1 receptor and its ligand (PD-1/PD-L1) have transformed the management …
The Promise of Genomics and the Development of Targeted Therapies for Cutaneous Squamous Cell Carcinoma.
Harwood CA, Proby CM, Inman GJ, Leigh IM. Harwood CA, et al. Acta Derm Venereol. 2016 Jan;96(1):3-16. doi: 10.2340/00015555-2181. Acta Derm Venereol. 2016. PMID: 26084328 Free article. Review.
Targeted therapies for melanoma and basal cell carcinoma have evolved from deciphering the molecular mechanisms involved in their tumorigenesis. Mutations in BRAF have led to clinical use of BRAF-inhibitors in advanced melanoma, and mutations in Hedgehog sign …
Targeted therapies for melanoma and basal cell carcinoma have evolved from deciphering the molecular mechanisms involve …
81 results